3 minute read

INOVIQ

DR LEEARNE HINCH

CEO

(ASX:IIQ )

◾ Company Name: INOVIQ ◾ Company ASX code: IIQ ◾ Key areas: Exosome capture tools and precision diagnostics for cancer and other diseases ◾ Key Personnel: Dr Leearne Hinch, CEO | Dr Gregory Rice, Chief Scientific Office | Dr Rocco Iannello, Business Development and Licensing Director ◾ Locations: Australia and United States ◾ Market Cap as of 15/09/22: $62.11M ◾ 52 Week share price as of 15 September: $0.385 - $1.500 ◾ Company Website: inoviq.com

COMPANY PROFILE

INOVIQ is developing and commercialising next generation exosome capture tools and precision diagnostics for the screening, diagnosis, prognosis and monitoring of cancer and other diseases.

The global cancer diagnostics market is worth $US250 billion, and INOVIQ is targeting markets worth over $US15 billion for some of the most common and deadliest cancers.

INOVIQ is using its patented biomarker isolation and detection technologies and a multiomics approach to develop earlier and more accurate diagnostics to improve outcomes for patients with cancer and other diseases.

The company’s diagnostics pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast and other cancers.

INOVIQ already has two products inmarket - its EXO-NET® research tool for pan-exosome capture and its hTERT test for bladder cancer detection.

EXO-NET pan-exosome capture is a ‘research use only’ product for the isolation of exosomes from blood and other body fluids with speed, purity, and yield advantages. EXO-NET meets an unmet need for fast, precise and scalable isolation of exosomes for research and commercial applications.

Exosomes are extracellular vesicles released by cells that carry biomolecules such as DNA, RNAs, proteins and lipids that can have important applications in the research, diagnosis and treatment of cancer, inflammatory, metabolic, and neurodegenerative diseases.

INOVIQ recently hit a key milestone on the path to global expansion, accelerating the commercial roll-out of its EXO-NET research products in North America by engaging Percorso Life Sciences for sales and logistics services. The global exosome research market is expected to reach $US661m by 2026, with the US accounting for 41.5% of the market.

In April 2022, INOVIQ announced its first EXO-NET collaboration with the University of Queensland to develop a world-first exosome-based ovarian cancer screening test. This blood test could fill an important unmet need for an accurate and reliable screening test for ovarian cancer to improve women’s health outcomes and save lives.

The company’s proprietary SubB2M technology detects the pan-cancer biomarker Neu5Gc found at elevated levels in multiple human cancers.

SubB2M immunoassays are being developed to “supercharge” existing FDA-approved blood tests for monitoring ovarian and breast cancers, and a SubB2M-SPR test is also being evaluated to detect Neu5Gc as a pan-cancer indicator in a general health panel.

In May 2022, INOVIQ executed an agreement with MP Biomedicals, a global supplier of life science and diagnostic products, for the contract manufacture of the SubB2M protein.

In April 2022, contract diagnostics firm ResearchDx was engaged to further develop and validate the SubB2M-based tests, with the SubB2M/CA15.3 and SubB2M/CA125 immunoassays for breast and ovarian cancer monitoring expected to commence clinical studies by the end of 2022.

INOVIQ’s team has a strong track record in healthcare, diagnostic development, and commercialisation and is building a strong footprint in the exosome and diagnostics markets.

CEO Dr Leearne Hinch is an experienced biotechnology executive with expertise in corporate development, capital raising, product development, commercialisation and licensing.

CSO Dr Greg Rice is an internationally recognised academic and commercial scientist with over 30 years of experience in oncology, perinatology, exosome-based research, clinical translational research, IVD development and commercialisation.

KEY INVESTMENT HIGHLIGHTS

APRIL 1, 2022: INOVIQ and the University of Queensland expand collaboration to develop world-first exosome-based ovarian cancer screening test. APRIL 5, 2022: INOVIQ signs agreement with US-based contract diagnostics organisation ResearchDx to develop and validate SubB2M test for the monitoring of breast and ovarian cancers. JULY 21, 2022: INOVIQ accelerates commercial roll-out of its EXO-NET research products in North America with engagement of US-based contract sales team.

This article is from: